今日の臨床サポート 今日の臨床サポート
関連論文:
img  11:  Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases.
 
著者: Rein Willemze, Patty M Jansen, Lorenzo Cerroni, Emilio Berti, Marco Santucci, Chalid Assaf, Marijke R Canninga-van Dijk, Agnes Carlotti, Marie-Louise Geerts, Sonja Hahtola, Michael Hummel, Leila Jeskanen, Werner Kempf, Cesare Massone, Pablo L Ortiz-Romero, Marco Paulli, Tony Petrella, Annamari Ranki, José L Rodriguez Peralto, Alistair Robson, Nancy J Senff, Maarten H Vermeer, Janine Wechsler, Sean Whittaker, Chris J L M Meijer, EORTC Cutaneous Lymphoma Group
雑誌名: Blood. 2008 Jan 15;111(2):838-45. doi: 10.1182/blood-2007-04-087288. Epub 2007 Oct 12.
Abstract/Text In the WHO classification, subcutaneous panniculitis-like T-cell lymphoma (SPTL) is defined as a distinct type of T-cell lymphoma with an aggressive clinical behavior. Recent studies suggest that distinction should be made between SPTL with an alpha/beta T-cell phenotype (SPTL-AB) and SPTL with a gammadelta T-cell phenotype (SPTL-GD), but studies are limited. To better define their clinicopathologic features, immunophenotype, treatment, and survival, 63 SPTL-ABs and 20 SPTL-GDs were studied at a workshop of the EORTC Cutaneous Lymphoma Group. SPTL-ABs were generally confined to the subcutis, had a CD4-, CD8+, CD56-, betaF1+ phenotype, were uncommonly associated with a hemophagocytic syndrome (HPS; 17%), and had a favorable prognosis (5-year overall survival [OS]: 82%). SPTL-AB patients without HPS had a significantly better survival than patients with HPS (5-year OS: 91% vs 46%; P<.001). SPTL-GDs often showed (epi)dermal involvement and/or ulceration, a CD4-, CD8-, CD56+/-, betaF1- T-cell phenotype, and poor prognosis (5-year OS: 11%), irrespective of the presence of HPS or type of treatment. These results indicate that SPTL-AB and SPTL-GD are distinct entities, and justify that the term SPTL should further be used only for SPTL-AB. SPTL-ABs without associated HPS have an excellent prognosis, and multiagent chemotherapy as first choice of treatment should be questioned.

PMID 17934071  Blood. 2008 Jan 15;111(2):838-45. doi: 10.1182/blood-2007-04-087288. Epub 2007 Oct 12.
戻る

さらなるご利用にはご登録が必要です。

こちらよりご契約または優待日間無料トライアルお申込みをお願いします。

(※トライアルご登録は1名様につき、一度となります)


ご契約の場合はご招待された方だけのご優待特典があります。

以下の優待コードを入力いただくと、

契約期間が通常12ヵ月のところ、14ヵ月ご利用いただけます。

優待コード: (利用期限:まで)

ご契約はこちらから